| 000 | 01799 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517103838.0 | ||
| 264 | 0 | _c20170424 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1559-131X | ||
| 024 | 7 |
_a10.1007/s12032-016-0803-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIriyama, Noriyoshi | |
| 245 | 0 | 0 |
_aPlasma cell maturity as a predictor of prognosis in multiple myeloma. _h[electronic resource] |
| 260 |
_bMedical oncology (Northwood, London, England) _cAug 2016 |
||
| 300 |
_a87 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 |
_aIntegrin alpha5 _xanalysis |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xanalysis |
| 650 | 0 | 4 |
_aPlasma Cells _xpathology |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aMiura, Katsuhiro | |
| 700 | 1 | _aHatta, Yoshihiro | |
| 700 | 1 | _aUchino, Yoshihito | |
| 700 | 1 | _aKurita, Daisuke | |
| 700 | 1 | _aTakahashi, Hiromichi | |
| 700 | 1 | _aSakagami, Hitomi | |
| 700 | 1 | _aSakagami, Masashi | |
| 700 | 1 | _aKobayashi, Yujin | |
| 700 | 1 | _aNakagawa, Masaru | |
| 700 | 1 | _aOhtake, Shimon | |
| 700 | 1 | _aIizuka, Yoshikazu | |
| 700 | 1 | _aTakei, Masami | |
| 773 | 0 |
_tMedical oncology (Northwood, London, England) _gvol. 33 _gno. 8 _gp. 87 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12032-016-0803-3 _zAvailable from publisher's website |
| 999 |
_c26196103 _d26196103 |
||